To determine whether the PDXGEM predictor has erlotinib-specificity, we produced PDXGEM scores for 20 patients with the NSCLC subtype lung squamous carcinoma who did not receive erlotinib or other EGFR inhibitors (GSE68793). This evidence concerns the gene EGFR and non-small cell lung carcinoma.